Dr. Tao, Mi-Hua 's orcid link picture Dr. Tao, Mi-Hua 's publons link picture

Dr. Tao, Mi-Hua

Research Fellow
  • 02-2789-9151 (L) (Lab) (Room No: N229)
  • 02-2652-3078 (O) (Office)
  • 02-2782-9142 (Fax)

Specialty:
  • Viral and Cancer Immunology
  • Viral and Cancer Immunotherapy
  • Vaccine Development
  • Gene Therapy

Education and Positions:
  • Ph.D.  Columbia University (Microbiology and Immunology).

    Postdoctoral Fellow.  Stanford University (Oncology)


  • 日常維護流程─ FACSCelesta
  • 感染性檢體流式細胞儀使用規則(2017)

  • Highlight Detail
    ...

    CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge

    Dr. Tao, Mi-Hua
    Scientific Report, Apr 22, 2021

    The COVID-19 pandemic presents an unprecedented challenge to global public health. Rapid development and deployment of safe and effective vaccines are imperative to control the pandemic. In the current study, we applied our adjuvanted stable prefusion SARS-CoV-2 spike (S-2P)-based vaccine, MVC-COV1901, to hamster models to demonstrate immunogenicity and protection from virus challenge. Golden Syrian hamsters immunized intramuscularly with two injections of 1 microg or 5 microg of S-2P adjuvanted with CpG 1018 and aluminum hydroxide (alum) were challenged intranasally with SARS-CoV-2. Prior to virus challenge, the vaccine induced high levels of neutralizing antibodies with 10,000-fold higher IgG level and an average of 50-fold higher pseudovirus neutralizing titers in either dose groups than vehicle or adjuvant control groups. Six days after infection, vaccinated hamsters did not display any weight loss associated with infection and had significantly reduced lung pathology and most importantly, lung viral load levels were reduced to lower than detection limit compared to unvaccinated animals. Vaccination with either 1 mug or 5 mug of adjuvanted S-2P produced comparable immunogenicity and protection from infection. This study builds upon our previous results to support the clinical development of MVC-COV1901 as a safe, highly immunogenic, and protective COVID-19 vaccine.